Linsidomine
From Wikipedia, the free encyclopedia
|
Linsidomine
|
|
| Systematic (IUPAC) name | |
| 3-Morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine | |
| Identifiers | |
| CAS number | ? |
| ATC code | C01 |
| PubChem | |
| Chemical data | |
| Formula | C6H10N4O2 |
| Mol. mass | 170.17 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Linsidomine is a vasodilator. Linsidomine (SIN-1) is a metabolite of the antianginal drug molsidomine and acts by releasing NO from the endothelial cells nonenzymatically. It also hyperpolarizes the cell membrane through influencing the sodium-potassium pump and thereby rendering it less responsive to adrenergic stimulation ). Linsidomine injection at a dose of 1 mg produces usable erection in about 70% of patients and full erection in up to 50% of patients . Linsidomine does not appear to be associated with priapism .
|
|||||||||||

